Abstract: The invention relates to the use of substances which are at least partly blocking one ionotropic acetylcholine receptor of the inner ear and/or a calcium-activated potassium channel functionally associated with said acetylcholine receptor of the inner ear for the manufacturing of a pharmaceutical composition or medicament for the treatment of tinnitus.

Abstract: Use of adamantane derivatives of the formula ##STR1## in which R1 and R2 are identical or different and can be hydrogen or straight-chained or branched alkyl groups having 1 to 6 carbon atoms, ortogether with the nitrogen atom can represent a heterocyclic group having 5 or 6 ring atoms,in which R3 and R4 are identical or different and can be hydrogen, straight-chained or branched alkyl groups having between 1 and 6 carbon atoms, cycloalkyl groups having 5 or 6 carbon atoms or a phenyl group, and in which R5 is hydrogen or a straight-chained or branched alkyl group having between 1 and 6 carbon atoms for treating diseases of the inner ear.